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ABSTRACT 
Objectives: The main aim of the study was to investigate the expression of Platelet-Derived Growth Factor Receptors alpha 
(PDGFR-alpha) and beta (PDGFR-beta) in malignant and benign ovarian tumors. We performed an analysis of the correlation 
of PDGFRs expression and stage of the disease, tumor grade and histopathological type of epithelial ovarian cancer (EOC). 
Additionally, we evaluated patient prognosis according to PDGFR expression.
Material and methods: Our study group was composed of 52 samples of EOCs, 35 samples of benign ovarian tumors 
(BOTs), and 21 samples of unchanged ovaries (UOs). The samples were collected from patients who had been operated on 
in the Division of Gynecological Surgery of the Poznan University of Medical Sciences.
Results: PDGFR-alpha was found to be expressed more frequently in cancer cells of EOCs, when compared with tumor 
cells of BOTs and epithelium of UOs. On the other hand, PDGFR-alpha receptors were present less frequently in the stroma 
of EOCs, when compared with the stroma of BOTs and UOs. Comparing the studied groups, there were no statistically 
significant differences in the expression of PDGFR-beta. The expression of both PDGFRs was not related to the FIGO stage, 
grade or histopathological type of EOCs. The expression of the PDGFR-beta receptor in cancer cells was associated with 
an improved overall survival among patients with EOCs. Patient prognosis was not affected by either PDGFR-alpha expres-
sion or by PDGFR-beta tumor stroma expression. 
Conclusions: The expression of PDGFR-alpha is significantly different when comparing EOCs, BOTs and UOs. However, the 
prognosis of EOC only seems to be affected by PDGFR-beta expression in cancer cells. 
Key words: platelet-derived growth factor; platelet-derived growth factor receptor; ovarian malignancies, epithelial  
ovarian cancer
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause of 
death from gynecological malignancies and the ﬁfth leading 
cause of cancer-related death among women in the Western 
World [1]. Although complete remission after primary treat-
ment is achieved in approximately half of patients, the ma-
jority will relapse, and the disease then becomes fatal [2, 3]. 
The poor prognosis of ovarian cancer patients has motivated 
the development of new anti-cancer therapies. Recently, an-
tiangiogenic treatments have been introduced, and several 
trials have reported encouraging results in the management 
of patients with ovarian cancer. Two 3rd phase clinical trials 
evaluated the addition of anti-VEGF monoclonal antibody 
(bevacizumab) to the primary chemotherapy in patients 
with ovarian cancer [4]. However the results were far from 
what was expected — only the ICON7 study indicated a pro-
243
Sebastian Szubert et al., PDGFRs expression in ovarian cancer
www. journals.viamedica.pl/ginekologia_polska
longed overall survival rate in the group of patients with 
high-risk, non-optimally debulked ovarian cancer [5].There 
are multiple theories trying to explain lack of the efficacy 
of an anti-VEGF blockade, and one of them postulates the 
role of other than VEGF proangiogenic factors, which may 
stimulate the development of new blood vessels [6]. Thus, 
it is believed, that a combined inhibition of various proan-
giogenic pathways may exert more pronounced clinical 
benefits [7]. 
One group of growth factors which contributes to an-
giogenesis are the platelet-derived growth factors (PDGFs). 
The PDGFs family includes five growth factors: PDGF-AA, 
PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. These growth 
factors are homo- or hetero-dimers, each composed of two 
of the following polypeptides: PDGF-A, PDGF-B, PDGF-C, and 
PDGF-D. The PDGFs are ligands for receptors: PDGFR-alpha 
(for PDGF- AA, AB, BB, CC) and PDGFR-beta (for PDGF-BB, 
DD and less for AB). PDGFs play an important role in many 
physiological and pathological processes — like wound 
healing, bone development, erythropoiesis, atherosclerosis, 
and fibrosis. They act as typical growth factors, thus, they 
also play a role in cancerogenesis [8]. PDGF-PDGFR pathway 
activation is observed in multiple steps essential for cancer 
development, including uncontrolled proliferation, evad-
ing growth suppressors, resisting cell death, infiltration, 
metastasis, and immune system evasion [9–12]. Matei et al. 
[13], have shown that autocrine activation of PDGFR-alpha 
stimulates proliferation of ovarian cancer cells. Lassus et al. 
[14] reported that the expression of PDGFR-alpha in serous 
ovarian cancer cells correlates with a high mitotic index. 
Furthermore, inhibition of PDGFR signaling leads to tumor 
cell apoptosis, and a decrease in microvascular density and 
of the tumor cell proliferation rate [15]. Matsuo et al. [16], 
showed that blocking PDGFR-alpha activity with monoclo-
nal antibodies increases the sensitivity of carcinoma cells 
to docetaxel. PDGFs are also suspected to facilitate angio-
genesis during cancer development. PDGF-AA, PDGF-BB, 
and PDGF-AB are expressed within endothelial cells (ECs). 
Of these three growth factors, probably PDGF-BB has the 
most important impact on angiogenesis, as it directly 
stimulates ECs proliferation, migration, and tube forma-
tion, and inhibits ECs apoptosis [17]. Additionally, PDGF-B 
action through PDGFR-beta is responsible for pericyte 
vessel coverage, and thus, for vessel maturation [18, 19]. 
On the other hand, it was shown that significant vascular 
abnormalities develop in PDGFR-alpha knockout mice [20]. 
PDGFs can also indirectly stimulate angiogenesis by increas-
ing expression of VEGF [21]. Furthermore, recent studies in-
dicate PDGFs are involved not only in vascular development, 
but they also have a prominent role in lymphaniogenesis [22]. 
Taken together, these data support the important role of 
PDGFs in ovarian cancer development and angiogenesis. 
Recently, protein kinase inhibitors, targeting among 
others the PDGF-PDGFRs axis, were introduced for clini-
cal trial in ovarian cancer [4]. However, targeted therapy 
requires the appropriate selection of patients who may 
benefit from this novel therapy. Thus, the main aim of our 
study was to investigate the expression of PDGFR-alpha and 
PDGFR-beta in epithelial ovarian cancer. We have compared 
the expression of both receptors with their presence in BOTs 
and UOs. Additionally, we performed an analysis of PDGFRs 
expression and its correlation with selected clinicopatho-
logical features of the disease. Finally, because data on the 
impact of PDGFRs expression on EOC patient prognosis is 
sparse, we evaluated the expression of PDGFRs in terms of 
the overall survival (OS) rates of patients with EOC.
MATERIAL AND METHODS
The study group was composed of 52 samples of epi-
thelial ovarian cancer (EOCs). All samples were collected 
from patients operated on in the Division of Gynecological 
Surgery, at the Poznan University of Medical Sciences, dur-
ing primary surgery. The control group included 35 benign 
ovarian tumors (BOTs) and 21 samples of unchanged ovaries 
(UOs) obtained for non-oncological reasons. The tumors 
and ovarian samples were fixed in 10% formalin for immu-
nohistochemical study. The expression of PDGFR-alpha and 
PDGFR-beta was assessed by means of immunohistochemis-
try using the ImmunoMax technique [23]. The following anti-
bodies were used for the immunohistochemical evaluation: 
PDGF Receptor alpha – monoclonal mouse anti-human an-
tibody; dilution 1:1000; clone MM0004-8A89, Novus Biologi-
cals®, catalogue number: NB110-60969; and PDGF Receptor 
beta – monoclonal mouse anti-human antibody; dilution 
1:500, clone MM0005-5C37, Novus Biologicals®, catalogue 
number: NB110-60970. Both, the tumor cells/ovarian epi-
thelium and tumor/ovarian stroma were evaluated for the 
presence of the PDGFR-alpha and -beta. We observed only 
cytoplasmic PDGFRs staining pat tern, both in the tumors 
and in the UOs. The expression of PDGFRs was evaluated 
using subjective assessment of PDGFRs immunoreactivity. 
The PDGFRs expression was assessed as negative, when less 
than 5% of cells presented immunoreactivity for PDGFR. 
Representative images are presented in the Figure 1. 
Forty patients were available for follow-up. In this group, 
the patients’ survival rates were analyzed in relation to PDG-
FRs expression. The median patient follow-up was 1238 days 
(range 28–4550). Information on patients who died was 
retrieved from the database of the regional office of the 
National Health System of Poland.
The statistical analysis was performed using MedCalc 
(11.4.2.0) and GraphPad (3.06) software. The distribution 
of the variables in the study groups was verified using the 
Shapiro-Wilk test. Parametric or non-parametric tests were 
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used for evaluation according to the data distribution. The 
differences in patient age and BMI were determined using 
the Kruskal-Wallis Test with post-hoc Dunn’s Multiple Com-
parisons Test. The differences between the expressions of 
PDGFRs between studied groups were analyzed using the 
Fisher exact test. In the case of malignant ovarian tumors, 
the Fisher exact test was also used for the analysis of the 
differences in PDGFRs expression according to the tumor 
grade and the FIGO stage of the disease. We have used Chi 
square test for the analysis of PDGFR expression according 
to the histopathological type of the disease. Survival analy-
sis was conducted using Kaplan-Meier survival curves and 
the differences in patient survival were determined using 
log-rank test. 
Our research plan was approved by the University of 
Medical Science Poznan’s Bioethical Committee (Number: 
181/07).
RESULTS
The median age of patients in the group with EOCs was 
53 years (range: 34–85), whereas in the group with BOTs it 
was 43 years (14–80). The median age in the UOs group 
was 50 years (44–67). The difference between the patients’ 
ages was statistically significant (P = 0.002), whereas the 
posthoc tests only showed statistically significant differ-
ences between the group with malignant ovarian tumors 
and that with benign ovarian tumors (P < 0.01). The me-
dian body mass index (BMI) in the group with EOCs was 
25.7 (range: 17.9–49.7), while in the group with BOTs and 
in the UOs group, the median BMI was 24.8 (18.5–37.3) and 
25.2 (17.8–29.4) respectively. This latter difference was not 
statistically significant (P = 0.199).
The histopathological diagnoses of the tumors are sum-
marized in Table 1. Among the EOCs there were nine tumors 
at stage I, 10 at stage II, 24 at stage III and 9 at (FIGO) stage IV. 
Figure 1. Representative pictures of PDGFRs expression in cancer cells and tumor stroma. A. Ovarian serous adenocarcinoma with strong PDGFR-
alpha immunoreactivity in cancer cell cytoplasms, and moderate PDGFR-alpha immunoreactivity in the tumor stroma. B. The same tumor as 
on the picture A, showing strong PDGFR-beta immunoreactivity in cancer cell cytoplasm, and moderate PDGFR-beta immunoreactivity in the 
tumor stroma. C. Ovarian serous adenocarcinoma with weak PDGFR-alpha immunoreactivity in cancer cell cytoplasms, and weak PDGFR-alpha 
immunoreactivity in the tumor stroma. D. The same tumor as on the picture C, showing moderate PDGFR-beta immunoreactivity in cancer cell 
cytoplasm, and weak PDGFR-beta immunoreactivity in the tumor stroma. Magnification 200x for A–D
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Grading of malignant tumors was as follows: G1 — 11 tu-
mors, G2 — 10 tumors and G3 — 31 tumors.
The expression of the PDGF-alpha receptor was analyzed 
in 52 samples of EOCs, in 34 BOTs and in 18 samples of UOs, 
while the expression of the PDGF-beta receptor was ana-
lyzed in 52, 35 and 18 samples respectively. PDGFR-alpha 
expression was found in neoplastic cells in 33% of the ma-
lignant ovarian tumors and in 20% of the benign ovarian tu-
mors. There was no PDGFR-alpha expression in the epithe-
lium of the UOs. PDGFR-alpha expression between each of 
the groups studied was found to differ, and the difference 
was statistically significant (P = 0.008). Similarly, there were 
statistically significant differences in PDGFR-alpha expres-
sion in the analyzed groups (P = 0.005). PDGFR-alpha was 
found in the stroma of 83% of the UOs, 40% of the EOCs and 
in 58% of the BOTs. There were no significant differences in 
the expression of PDGFR-beta between the studied groups, 
both in either of the neoplastic cells/epithelium (P = 0.07) or 
the stroma (P = 0.29). The PDGF receptors expression results 
are shown in Table 2.
PDGFR-alpha expression differed in neither the tumor 
cells (P = 0.76) nor in the stroma (P = 0.55) between early 
and advanced malignant ovarian tumors (Tab. 3). Similarly, 
PDGFR-beta expression did not differ between the analyzed 
subgroups (tumor cells — P = 0.09; stroma — P = 0.76). There 
were no differences in PDGFRs expression between the EOCs 
of G1 and G2/3. These results are shown in Table 4.There 
were no differences in the expression of PDGF receptors 
between different histological types of ovarian cancer. Those 
results are summarized in Table 5. 
Patients with PDGFR-beta expression in cancer cells 
of EOC (10 patients) had significantly higher median OS 
compared with patients without PDGFR-beta expression 
(30 patients) in cancer cells (3506 days, range 526–3966 vs 
891 days, 28–4550, respectively, P = 0.04). There was no 
significant difference regarding patient survival in rela-
tion to PDGFR-beta expression in the stroma of EOC. Pa-
tients with PDGFR-beta expression in the tumor stroma 
(21 patients) had a median survival of 1247 days (range 
Table 1. Histopathological diagnoses of ovarian tumors in the 
study group




Clear — cell adenocarcinoma 4
Undifferentiated carcinoma 11










tumors Unchanged ovaries P value
PDGFR-alpha
neoplastic cells/epithelial cells 33% (17/52) 20% (7/34) 0 (0/18) P = 0.008
PDGFR-alpha
stroma neoplasm/normal ovary 40% (21/52) 58% (20/34) 83% (15/18) P = 0.005
PDGFR-beta
neoplastic cells/epithelial cells 23% (12/52) 14% (5/35) 0 (0/18) P = 0.07
PDGFR-beta
stroma neoplasm/normal ovary 63% (33/52) 50% (17/35) 67% (12/18) P = 0.29
Table 3. Expression of PDGF receptors according to FIGO stage
FIGO I and II FIGO III and IV P value
PDGFR-alpha
carcinoma cells (+) 37% (7/19) 30% (10/33) P = 0.76
PDGFR-alpha
stroma (+) 47% (9/19) 36% (12/33) P = 0.55
PDGFR-beta
carcinoma cells (+) 37% (7/19) 15% (5/33) P = 0.09
PDGFR-beta
stroma (+) 68% (13/19) 60% (20/33) P = 0.76
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28–4550), when compared with 1229 days (range 106–3402) 
for the patients without PDGFR-beta expression in the tu-
mor stroma (P = 0.84). Patient prognosis was unaffected 
by PDGFR-alpha expression. Patients with PDGFR-alpha 
expression (10 patients) in cancer cells had a median sur-
vival of 2314 days (range 526–4550), while patients with no 
PDGFR-alpha expression (30 patients) in cancer cells had 
a median OS of 1012 (28–3966 days; P = 0.19). Patients with 
PDGFR-alpha expression in tumor stroma (14 patients) had 
an insignificantly higher median OS compared with patients 
without PDGFR-alpha expression (26 patients) in tumor 
stroma (1924 days, range 364–4550 vs 913 days, 28–3966, 
respectively, P = 0.40). Figure 2 presents the survival curves 
corresponding to the elements referred to here. 
DISCUSSION
In our study we observed significant differences in 
PDGFR-alpha expression between EOCs, BOTs and UOs. The 
differences were found both in the cancer cells and in the 
tumor stroma. On the other hand, there were no differ-
ences in the expression of PDGFR-beta between the groups 
analyzed. Henriksen et al. assessed the expression of alpha 
and beta receptors for PDGF in ovarian cancer, benign ovar-
ian tumors and normal ovaries [24]. They demonstrated 
PDGFR-alpha expression in 16 of the 45 malignant ovar-
ian tumors, while they found no expression in the BOTs 
and the UOs. Expression in the stroma occurred in 17 of the 
45 malignant tumors, 9 of the 20 benign tumors and in all 
of the normal ovaires. These results are very similar to ours, 
except for the expression of PDGFR-alpha in the benign 
tumors, which occurred in 20% of the tumors in our study. 
Additionally, we have found PDGF-alpha expression in the 
stroma of 83% of the UOs [24]. Madsen et al. [25] observed 
PDGFR-alpha expression in cancer cells in 43% of EOCs, 
and in 32% of their stroma. A study by Wilczynski et al. [26] 
revealed similar results, namely, PDGFR-alpha expression in 
58% ovarian cancers and no expression in the epithelium 
of normal ovaries. We may conclude that the findings of 
these reports are compatible. In summary, about 30–58% 
of EOC express PDGFR-alpha in cancer cells. PDGFR-alpha 
expression is less frequently presented in benign ovar-
ian tumors. Three reports showed no expression of PDG-
FR-alpha in normal ovarian surface epithelium. In the case 
of PDGFR-alpha expression in the stroma, PDGFR-alpha 
immunoreactivity in the stroma is found in about one-third 
of EOCs, one-half of BOTs, and in most UOs. 
The main difference between our study and the study 
by Henriksen et al. is the expression of PDGFR-beta in neo-
plastic cells. Henriksen et al. did not observe PDGFR-beta 
expression in either ovarian cancer or benign ovarian tu-
mors cells, nor in normal ovarian epithelial cells. Howev-
er, our study showed PDGFR-beta expression in 20% of 
ovarian cancers and 14% of benign ovarian tumors. The 
presence of PDGFR-beta expression in ovarian cancer cells 
Table 4. Expression of PDGF receptors according to tumor grade
G1 G2/3 P value
PDGFR-alpha
carcinoma cells (+) 36% (4/11) 32% (13/41) P = 1.0
PDGFR-alpha
stroma (+) 54% (6/11) 37% (15/41) P = 0.31
PDGFR-beta
carcinoma cells (+) 27% (3/11) 22% (9/41) P = 0.68
PDGFR-beta
stroma (+) 64% (7/11) 63% (26/41) P = 1.0












carcinoma cells (+) 36% (9/25) 37.5% (3/8) 0% (0/4) 25% (1/4) 35.7% (4/11) P = 0.67
PDGFR-alpha
stroma (+) 40% (10/25) 50% (4/8) 25% (1/4) 0% (0/4) 54.5% (6/11) P = 0.36
PDGFR-beta
carcinoma cells (+) 24% (6/25) 37.5% (3/8) 25% (1/4) 0% (0/4) 21.4% (2/11) P = 0.68
PDGFR-beta
stroma (+) 64% (16/25) 75% (6/8) 25% (1/4) 50% (2/4) 54.5% (6/11) P = 0.52
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was also confirmed by other studies [24]. Apte et al. [15, 
17] reported both PDGFR-alpha and PDGFR-beta expres-
sions in ovarian cancer cells from HeyA8 and SKOV3ip1 cell 
lines. Madsen et al. and Wilczynski et al. [25, 26] reported 
PDGFR-beta expression in 41% and 29% of ovarian cancers 
respectively.
Madsen et al. [25] showed PDGFR-beta expression in 
the stroma of 44% of ovarian cancers. Henriksen et al. [24] 
reported PDGFR-beta expression in the stroma of 20 of the 
21 unchanged ovaries studied, 21 of the 23 benign tumors, 
and 29 of the 45 ovarian cancers. The results of the two stud-
ies cited here corresponded with our observations. 
Henriksen et al. showed more frequent expression of 
PDGFR-alpha in serous ovarian cancer than in mucinous 
and endometrioid. In our study there were no statistically 
significant differences in the expression of PDGFR-alpha 
between the various histopathological types of malignant 
ovarian tumors. Madsen et al. also did not find a correlation 
between PDGFRs expression and the histopathological type 
of the tumor. In the Henriksen et al. [24] study previously 
cited, the authors showed no differences in the expression 
of PDGF receptors between the different grades and stages 
of malignant tumors; and this finding also corresponds with 
our results. Similarly, no relationships were noted between 
PDGFRs expression and tumor stage and grade in the study 
by Madsen et al. [25]. 
In our study we found the expression of PDGFR-beta 
receptor in cancer cells to be associated with improved over-
all survival of EOCs patients. Similar results were obtained 
by Dabrow et al. [27], who reported a two times higher 
median relapse-free survival in patients with PDGFR-beta 
expression in cancer cells. These results are in contrast to 
those of the study by Avril et al. [28], which found high 
expression of PDGFR-beta to be associated with shortened 
survival rates and with platinum-resistance. However, both 
we and Dabrow et al. have based our study on immunohisto-
chemistry techniques (assessment of PDGFR-beta immuno-
reactivity), while Avril et al. used reverse phase protein arrays 
to evaluate protein expression [27, 28]. Thus, the differences 
between the two sets of results may be explained by the 
studies’ different methods of assessment. 
We found no differences in EOC patient survival relating 
to the expression of PDGFR-beta in tumor stroma. Similarly, 
in the study by Madsen et al. [25], PDGFR-beta expression 
in tumor stroma did not affect patient survival. PDGFR-beta 
is expressed by a variety of non-cancerous cells infiltrating 
the tumor stroma, mainly Cancer-Associated Fibroblasts 
(CAFs) and pericytes. CAFs contribute to tumor stroma re-
Figure 2. Survival analyses according to PDGFR expression. A) Patients with PDGFR-alpha expression (10 patients) in cancer cells of EOC had 
a median overall survival (OS) of 2314 days (range 526–4550), vs 1012 days (28–3966) for the patients with no PDGFR-alpha expression (30 patients) 
in cancer cells (P = 0.19). B) Patients with PDGFR-alpha expression in tumor stroma (14 patients) had a median n median OS of 1924 days (range 364–
4550) vs  913 days (28–3966) for the patients without PDGFR-alpha expression (26 patients) in tumor stroma (P = 0.40). C) Patients with PDGFR-beta 
expression (10 patients) in cancer cells of EOC had a median OS of 3506 days (range 526–3966) vs 891 days  (28–4550) for the patients without PDGFR-
beta expression (30 patients) in cancer cells (P = 0.04). D) Patients with PDGFR-beta expression in the tumor stroma (21 patients) had a median survival 
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modeling, creating a tumor-friendly microenvironment. 
Multiple studies confirm the role of tumor stroma and CAFs 
in ovarian cancer development and progression [29, 30]. 
Additionally, the number of CAFs seems to correlate with 
patients’ poor prognosis, since EOC patients with stroma-rich 
tumors have a worse prognosis than patients with tumors 
characterized by poorly developed stroma [31]. On the other 
hand, recent studies have shown that pericyte coverage of 
vessels, by preventing cell migration and hematogenous 
metastasis, correlates with better  patient prognoses [32]. In 
our paper we did not differentiate PDGFR-beta expressing 
stroma cells. We presume that further studies evaluating 
the source of PDGFR-beta expression in tumor stroma may 
contribute to a better understanding of the prognostic role 
of PDGFR-beta expression in the stroma of EOCs. 
In our study, patient prognoses were not affected by 
PDGFR-alpha expression. Similar results were obtained by 
Madsen et al. [25]. However, in the study by Henriksen et al., 
patients with tumors expressing PDGFR-alpha in cancer cells 
had significantly shortened overall survival when compared 
with those with PDGFR-alpha negative tumors. The associa-
tion was also significant, when the evaluation was limited 
to twenty-three stage III EOC patients [24]. Similar results 
were obtained by Matsuo et al. [16], where the authors 
found that increased PDGFR-alpha expression is associated 
with poorer overall survival when compared with low, or 
no, PDGFR-alpha expression. Our study did not confirm the 
above observations. The discrepancy between these three 
studies may be explained by the fact that each of the studies 
was based on small populations of patients. Additionally, 
there is significant variability in the specificity of various 
sets of anti-PDGFR-alpha antibodies. Thus, the different 
antibodies used in each of the studies may have influenced 
the differences between the studies’ results [33]. 
Several trials have been conducted to evaluate the 
clinical utility of multipotential kinase inhibitors in the man-
agement of EOC. These drugs inhibit numerous signaling 
pathways involved in cancer development, including those 
of PDGFR-alpha and -beta. However, most of these drugs 
yield weak clinical responses, with no impact on patient 
prognosis [34]. The most promising results are related to the 
use of cediranib. Cediranib is a tyrosine kinase inhibitor that 
inhibits not only PDGFR-beta, but also all three members of 
the VEGFR family and c-KIT. A recent trial by Ledermann et al. 
[35] has shown significant prolongation of progression-free 
survival with cediranib when given during chemotherapy 
and then continued as maintenance therapy in women suf-
fering from platinum-sensitive EOC. However, considering 
that PDGFRs are expressed in less than half of EOC patients, 
and their impact on patient prognosis is not clear, it seems 
reasonable to investigate PDGFR when conducting trials of 
PDGFR-inhibitors. 
CONCLUSIONS
The expression of PDGFR-alpha, in contrast to PDG-
FR-beta, is significantly different between EOCs, BOTs and 
UOs. The expression of both PDGFRs is not affected by the 
clinical stage of the diseases, the tumor grade and the histo-
pathological type of EOC. The prognostic role of PDGFR-al-
pha expression in EOC needs further evaluation. However, 
the prognosis of EOC seems to be affected by PDGFR-beta 
expression in cancer cells. 
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